Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/27/2008 - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 11/13/2008 - (DGNews)
    Declining Benefit of Combination Therapy for Rheumatoid Arthritis Found in Long-Term Follow-Up of Patients: Presented at ACR-ARHP - (DGDispatch)
    Genetic Markers Point to Increased Risk of Infection in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Efficacy of Rituximab Is Sustained in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      B-Cell Biology and B-Cell-Targeted Therapies for Autoimmune Rheumatic Diseases: The Role of the Allied Health Professional
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      The Management of Difficult Rheumatoid Arthritis
      Expanding the Armamentarium for the Treatment of Juvenile Rheumatoid Arthritis: Update for Managed Care Pharmacists
      Hepatic Effects of Biologic Agents: Current and Future Issues in the Treatment of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Disseminated Cutaneous Herpes Simplex Virus-1 in a Patient with Rheumatoid Arthritis Receiving Infliximab: A Case Report
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Etanercept Safe, Effective Treatment for Rheumatoid Arthritis in Elderly Patients

        A DGReview of :"Response to Etanercept (Enbrel ® ) in Elderly Patients with Rheumatoid Arthritis: A Retrospective Analysis of Clinical Trial Results"
        Journal of Rheumatology

        05/21/2003
        By Deanna M. Green


        For patients over 65 with rheumatoid arthritis, etanercept is a potential treatment option that causes a rapid and sustained response, according to a recent study.

        Rheumatoid arthritis (RA) is most prevalent in patients older than 65 years, yet clinical studies on treatments for RA tend to under represent this group in their analyses.

        Special attention to the efficacy and safety of arthritis treatments in the elderly is necessary due to medical and health-related differences between the elderly and younger populations, such as increased likelihood of comorbidity, their susceptibility to serious infections and mortality from infections, lack of medication compliance, potential of multiple drug interactions, and decreased tolerability due to physiological changes.

        Etanercept is one treatment for RA that is well tolerated and produces significant sustained improvement in disease activity. However, the safety and efficacy of this therapy in patients over 65 has not been properly evaluated. Roy M. Fleischmann, MD, and colleagues conducted a retrospective study, sponsored by Immunex Corporation, Spokane, Washington, to determine the efficacy and safety of etanercept in this patient group.

        One hundred and ninety seven of 1,128 patents enrolled in 4 double-blind, randomised trials and 5 open-label etanercept trials were 65 years old or older. All patients had received etanercept subcutaneously twice weekly.

        The researchers found that at 3 months of treatment, 55% of patients over age 65 showed 20% improvement in the number of tender and swollen joints and in other American College of Rheumatology (ACR) criteria. After 1 year of treatment, the number of patients with 20% improvement increased to 66% of patients over 65.

        Furthermore, etanercept treatment was well tolerated, causing only mild adverse events. In fact, patients in this age group showed a lower rate of injection site reactions, headache, and rhinitis compared to younger patients.

        Deaths and cancer diagnoses in patients over 65 treated with etanercept were similar to that estimated for this age group within the general population.

        Etanercept "offers older patients with rheumatoid arthritis a rapid, predictable, and sustained clinical response, and is a significant addition to treatment options for these patients," notes Dr. Fleischmann.
        J Rheumatol 2003;30:4:691-696. "Response to Etanercept (Enbrel ® ) in Elderly Patients with Rheumatoid Arthritis: A Retrospective Analysis of Clinical Trial Results"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send